The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Chronic lymphocytic leukaemia
Open accessAbstract
Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and lymphoid tissues. Signalling via surface immunoglobulin, which constitutes the major part of the B cell receptor, and several genetic alterations play a part in CLL pathogenesis, in addition to interactions between CLL cells and other cell types, such as stromal cells, T cells and nurse-like cells in the lymph nodes. The clinical progression of CLL is heterogeneous and ranges from patients who require treatment soon after diagnosis to others who do not require therapy for many years, if at all. Several factors, including the immunoglobulin heavy-chain variable region gene (IGHV) mutational status, genomic changes, patient age and the presence of comorbidities, should be considered when defining the optimal management strategies, which include chemotherapy, chemoimmunotherapy and/or drugs targeting B cell receptor signalling or inhibitors of apoptosis, such as BCL-2. Research on the biology of CLL has profoundly enhanced our ability to identify patients who are at higher risk for disease progression and our capacity to treat patients with drugs that selectively target distinctive phenotypic or physiological features of CLL. How these and other advances have shaped our current understanding and treatment of patients with CLL is the subject of this Primer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Self-citationLichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationmiR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
Self-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Self-citationUnmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
Self-citationDamle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,642
Self-citationA MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia
Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050995 · Cited by 2,403
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Self-citationHallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationA comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Self-citationIbrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Self-citationObinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Charting a dynamic DNA methylation landscape of the human genome
Ziller, M. J., Gu, H., Müller, F., Donaghey, J., Tsai, L. T.-Y., Kohlbacher, O., De Jager, P. L., Rosen, E. D., Bennett, D. A., Bernstein, B. E., et al. (2013) · Nature · doi:10.1038/nature12433 · Cited by 1,357
Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,299
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Lam, K.-P., Kühn, R., & Rajewsky, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80373-6 · Cited by 1,108
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,080
Self-citationMutations driving CLL and their evolution in progression and relapse
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. (2015) · Nature · doi:10.1038/nature15395 · Cited by 1,068
Self-citationQuesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez-Trillos, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 996
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice
Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., & Croce, C. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602266103 · Cited by 951
Self-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Self-citationFais, F., Ghiotto, F., Hashimoto, S., Sellars, B., Valetto, A., Allen, S. L., Schulman, P., Vinciguerra, V. P., Rai, K., Rassenti, L. Z., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3009 · Cited by 872
Self-citationLenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., Ambesi-Impiombato, A., Califano, A., Migliazza, A., Bhagat, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.019 · Cited by 848
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 829
Herishanu, Y., Pérez-Galán, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284984 · Cited by 815
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C.-M., Roberts, A. W., Jurczak, W., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 805
Self-citationFriedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J. P., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236471 · Cited by 747
Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J., Gribben, J. G., Neuberg, D. S., Flinn, I. W., Rai, K. R., Byrd, J. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040857 · Cited by 745
Self-citation(2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30029-8 · Cited by 672
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Self-citationEichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Rawstron, A. C., Bennett, F. L., O'Connor, S. J. M., Kwok, M., Fenton, J. A. L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075290 · Cited by 613
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv303 · Cited by 612
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110921 · Cited by 610
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608
Burger, J. A., Tsukada, N., Burger, M., Zvaifler, N. J., Dell'Aquila, M., & Kipps, T. J. (2000) · Blood · doi:10.1182/blood.v96.8.2655 · Cited by 607
Self-citationRamsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Self-citationOfatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Self-citationHuman chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
Bichi, R., Shinton, S. A., Martin, E. S., Koval, A., Calin, G. A., Cesari, R., Russo, G., Hardy, R. R., & Croce, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102181599 · Cited by 582
Self-citationEpigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
Kulis, M., Heath, S., Bibikova, M., Queirós, A. C., Navarro, A., Clot, G., Martínez-Trillos, A., Castellano, G., Brun-Heath, I., Pinyol, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2443 · Cited by 578
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 554
From pathogenesis to treatment of chronic lymphocytic leukaemia
Zenz, T., Mertens, D., Küppers, R., Döhner, H., & Stilgenbauer, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2764 · Cited by 553
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2016) · Nature · doi:10.1038/nature18910 · Cited by 546
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Germinal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510
Burger, J. A., Burger, M., & Kipps, T. J. (1999) · Blood · doi:10.1182/blood.v94.11.3658 · Cited by 507
Self-citationThompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., Smith, S. C., Kantarjian, H. M., Freireich, E. J., & Keating, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-667675 · Cited by 505
Self-citationChronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Minden, M. D.-V., Übelhart, R., Schneider, D., Wossning, T., Bach, M. P., Buchner, M., Hofmann, D., Surova, E., Follo, M., Köhler, F., et al. (2012) · Nature · doi:10.1038/nature11309 · Cited by 504
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Izcue, A., Coombes, J. L., & Powrie, F. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00423.x · Cited by 474
Rossi, D., Rasi, S., Spina, V., Bruscaggin, A., Monti, S., Ciardullo, C., Deambrogi, C., Khiabanian, H., Serra, R., Bertoni, F., et al. (2013) · Blood · doi:10.1182/blood-2012-09-458265 · Cited by 467
Eichhorst, B., Hallek, M., & Dreyling, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq180 · Cited by 456
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Orchard, J. A., Ibbotson, R. E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P. W., Hamblin, T. J., Staudt, L. M., & Oscier, D. G. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15260-9 · Cited by 448
Döhner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M., Fischer, K., Hunstein, W., & Lichter, P. (1997) · Blood · doi:10.1182/blood.v89.7.2516 · Cited by 439
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia
Lu, D., Zhao, Y., Tawatao, R., Cottam, H. B., Sen, M., Leoni, L. M., Kipps, T. J., Corr, M., & Carson, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308648100 · Cited by 420
Self-citationThe Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950–2001
Hsu, W.-L., Preston, D. L., Soda, M., Sugiyama, H., Funamoto, S., Kodama, K., Kimura, A., Kamada, N., Dohy, H., Tomonaga, M., et al. (2013) · Radiation Research · doi:10.1667/rr2892.1 · Cited by 409
Landau, D. A., Clement, K., Ziller, M. J., Boyle, P., Fan, J., Gu, H., Stevenson, K., Sougnez, C., Wang, L., Li, S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.012 · Cited by 394
Self-citationAgathangelidis, A., Darzentas, N., Hadzidimitriou, A., Brochet, X., Murray, F., Yan, X.-J., Davis, Z., van Gastel-Mol, E. J., Tresoldi, C., Chu, C. C., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393694 · Cited by 393
Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., Arcaini, L., Lucioni, M., Rocque, G. B., Xu-Monette, Z. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-09-302174 · Cited by 386
Perturbation of the normal immune system in patients with CLL
Forconi, F., & Moss, P. (2015) · Blood · doi:10.1182/blood-2015-03-567388 · Cited by 385
Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic Leukemia
A Randomized, C. C. T. C. G. F. T. S. O. I. I. C. L. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810063191403 · Cited by 367
Ramsay, A. G., Clear, A. J., Fatah, R., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-02-411678 · Cited by 358
Self-citationA genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia
Di Bernardo, M. C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., Sullivan, K., Vijayakrishnan, J., Wang, Y., Pittman, A. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.219 · Cited by 357
Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., et al. (2007) · Blood · doi:10.1182/blood-2005-12-051458 · Cited by 348
Self-citationB-cell anergy: from transgenic models to naturally occurring anergic B cells?
Cambier, J. C., Gauld, S. B., Merrell, K. T., & Vilen, B. J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2133 · Cited by 348
Burger, J. A., Landau, D. A., Taylor-Weiner, A., Bozic, I., Zhang, H., Sarosiek, K., Wang, L., Stewart, C., Fan, J., Hoellenriegel, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11589 · Cited by 345
Self-citationHillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., Doubek, M., Panagiotidis, P., Kimby, E., Schuh, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60027-7 · Cited by 343
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 337
Self-citationSomatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia
Tobin, G., Thunberg, U., Johnson, A., Thörn, I., Söderberg, O., Hultdin, M., Botling, J., Enblad, G., Sällström, J., Sundström, C., et al. (2002) · Blood · doi:10.1182/blood.v99.6.2262 · Cited by 329
Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J. E., Widhopf, G. F., Rassenti, L. Z., Cantwell, M. J., Prussak, C. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712148105 · Cited by 312
Self-citationOakes, C. C., Seifert, M., Assenov, Y., Gu, L., Przekopowitz, M., Ruppert, A. S., Wang, Q., Imbusch, C. D., Serva, A., Koser, S. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3488 · Cited by 307
Self-citationGenetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Fabbri, G., Khiabanian, H., Holmes, A. B., Wang, J., Messina, M., Mullighan, C. G., Pasqualucci, L., Rabadan, R., & Dalla-Favera, R. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131448 · Cited by 302
Fabbri, M., Bottoni, A., Shimizu, M., Spizzo, R., Nicoloso, M. S., Rossi, S., Barbarotto, E., Cimmino, A., Adair, B., Wojcik, S. E., et al. (2011) · JAMA · doi:10.1001/jama.2010.1919 · Cited by 293
Self-citationLampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C., Freedman, A. S., Jacobson, C. A., Armand, P., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707133 · Cited by 285
Self-citationDevelopment of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T., Bauer, K., Malchau, G., Rabe, K. G., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556399 · Cited by 283
Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice
Raveche, E. S., Salerno, E., Scaglione, B. J., Manohar, V., Abbasi, F., Lin, Y.-C., Fredrickson, T., Landgraf, P., Ramachandra, S., Huppi, K., et al. (2007) · Blood · doi:10.1182/blood-2007-02-071225 · Cited by 281
Management of adverse events associated with idelalisib treatment: expert panel opinion
Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O’Brien, S. M., Pagel, J. M., Poleski, M. H., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1022770 · Cited by 273
Self-citationWalter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Damm, F., Mylonas, E., Cosson, A., Yoshida, K., Della Valle, V., Mouly, E., Diop, M., Scourzic, L., Shiraishi, Y., Chiba, K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0104 · Cited by 267
Byrd, J. C., Gribben, J. G., Peterson, B. L., Grever, M. R., Lozanski, G., Lucas, D. M., Lampson, B., Larson, R. A., Caligiuri, M. A., & Heerema, N. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1021 · Cited by 257
Self-citationChigrinova, E., Rinaldi, A., Kwee, I., Rossi, D., Rancoita, P. M. V., Strefford, J. C., Oscier, D., Stamatopoulos, K., Papadaki, T., Berger, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-489518 · Cited by 253
Widhopf, G. F., Rassenti, L. Z., Toy, T. L., Gribben, J. G., Wierda, W. G., & Kipps, T. J. (2004) · Blood · doi:10.1182/blood-2004-03-0818 · Cited by 251
Self-citationThompson, P. A., O'Brien, S. M., Wierda, W. G., Ferrajoli, A., Stingo, F., Smith, S. C., Burger, J. A., Estrov, Z., Jain, N., Kantarjian, H. M., et al. (2015) · Cancer · doi:10.1002/cncr.29566 · Cited by 245
Self-citationQuiroga, M. P., Balakrishnan, K., Kurtova, A. V., Sivina, M., Keating, M. J., Wierda, W. G., Gandhi, V., & Burger, J. A. (2009) · Blood · doi:10.1182/blood-2009-03-212837 · Cited by 237
Self-citationRossi, D., Spina, V., Cerri, M., Rasi, S., Deambrogi, C., De Paoli, L., Laurenti, L., Maffei, R., Forconi, F., Bertoni, F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3266 · Cited by 228
Kipps, T. J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P., & Carson, D. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5913 · Cited by 228
Self-citationIan Mockridge, C., Potter, K. N., Wheatley, I., Neville, L. A., Packham, G., & Stevenson, F. K. (2007) · Blood · doi:10.1182/blood-2006-11-056648 · Cited by 227
Self-citationMonoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management
Shanafelt, T. D., Ghia, P., Lanasa, M. C., Landgren, O., & Rawstron, A. C. (2010) · Leukemia · doi:10.1038/leu.2009.287 · Cited by 227
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk
Crowther-Swanepoel, D., Broderick, P., Di Bernardo, M. C., Dobbins, S. E., Torres, M., Mansouri, M., Ruiz-Ponte, C., Enjuanes, A., Rosenquist, R., Carracedo, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.510 · Cited by 225
Cervantes-Gomez, F., Lamothe, B., Woyach, J. A., Wierda, W. G., Keating, M. J., Balakrishnan, K., & Gandhi, V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2809 · Cited by 222
Self-citationEndo, T., Nishio, M., Enzler, T., Cottam, H. B., Fukuda, T., James, D. F., Karin, M., & Kipps, T. J. (2007) · Blood · doi:10.1182/blood-2006-06-027755 · Cited by 221
Self-citationRossi, D., Terzi-di-Bergamo, L., De Paoli, L., Cerri, M., Ghilardi, G., Chiarenza, A., Bulian, P., Visco, C., Mauro, F. R., Morabito, F., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647925 · Cited by 217
Ferreira, P. G., Jares, P., Rico, D., Gómez-López, G., Martínez-Trillos, A., Villamor, N., Ecker, S., González-Pérez, A., Knowles, D. G., Monlong, J., et al. (2014) · Genome Research · doi:10.1101/gr.152132.112 · Cited by 214
Second-generation inhibitors of Bruton tyrosine kinase
Wu, J., Liu, C., Tsui, S. T., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0313-y · Cited by 210
Cui, B., Chen, L., Zhang, S., Mraz, M., Fecteau, J.-F., Yu, J., Ghia, E. M., Zhang, L., Bao, L., Rassenti, L. Z., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559690 · Cited by 208
Self-citationGenome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia
Berndt, S. I., Skibola, C. F., Joseph, V., Camp, N. J., Nieters, A., Wang, Z., Cozen, W., Monnereau, A., Wang, S. S., Kelly, R. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2652 · Cited by 205
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia
Chen, L., Apgar, J., Huynh, L., Dicker, F., Giago-McGahan, T., Rassenti, L., Weiss, A., & Kipps, T. J. (2005) · Blood · doi:10.1182/blood-2004-05-1715 · Cited by 202
Self-citationNiemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1965 · Cited by 201
Bulian, P., Shanafelt, T. D., Fegan, C., Zucchetto, A., Cro, L., Nückel, H., Baldini, L., Kurtova, A. V., Ferrajoli, A., Burger, J. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8515 · Cited by 191
Villamor, N., Conde, L., Martínez-Trillos, A., Cazorla, M., Navarro, A., Beà, S., López, C., Colomer, D., Pinyol, M., Aymerich, M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.357 · Cited by 190
McClanahan, F., Hanna, B., Miller, S., Clear, A. J., Lichter, P., Gribben, J. G., & Seiffert, M. (2015) · Blood · doi:10.1182/blood-2015-01-622936 · Cited by 188
Self-citationWnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Yu, J., Chen, L., Cui, B., Widhopf, G. F., Shen, Z., Wu, R., Zhang, L., Zhang, S., Briggs, S. P., & Kipps, T. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83535 · Cited by 188
Self-citationSpeedy, H. E., Di Bernardo, M. C., Sava, G. P., Dyer, M. J. S., Holroyd, A., Wang, Y., Sunter, N. J., Mansouri, L., Juliusson, G., Smedby, K. E., et al. (2014) · Nature Genetics · doi:10.1038/ng.2843 · Cited by 187
Calissano, C., Damle, R. N., Marsilio, S., Yan, X.-J., Yancopoulos, S., Hayes, G., Emson, C., Murphy, E. J., Hellerstein, M. K., Sison, C., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00360 · Cited by 181
Self-citationFamilial predisposition and genetic risk factors for lymphoma
Cerhan, J. R., & Slager, S. L. (2015) · Blood · doi:10.1182/blood-2015-04-537498 · Cited by 178
DiLillo, D. J., Weinberg, J. B., Yoshizaki, A., Horikawa, M., Bryant, J. M., Iwata, Y., Matsushita, T., Matta, K. M., Chen, Y., Venturi, G. M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.165 · Cited by 175
O'Neill, S. K., Getahun, A., Gauld, S. B., Merrell, K. T., Tamir, I., Smith, M. J., Dal Porto, J. M., Li, Q.-Z., & Cambier, J. C. (2011) · Immunity · doi:10.1016/j.immuni.2011.10.011 · Cited by 165
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
Badoux, X. C., Keating, M. J., Wen, S., Lee, B.-N., Sivina, M., Reuben, J., Wierda, W. G., O'Brien, S. M., Faderl, S., Kornblau, S. M., et al. (2011) · Blood · doi:10.1182/blood-2011-03-339077 · Cited by 165
Self-citationLjungström, V., Cortese, D., Young, E., Pandzic, T., Mansouri, L., Plevová, K., Ntoufa, S., Baliakas, P., Clifford, R. M., Sutton, L., et al. (2015) · Blood · doi:10.1182/blood-2015-10-674572 · Cited by 162
Badoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158
Self-citationQueirós, A. C., Villamor, N., Clot, G., Martínez‐Trillos, A., Kulis, M., Navarro, A., Penas, E. M. M., Jayne, S., Majid, A., Richter, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.252 · Cited by 158
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Cui, B., Ghia, E. M., Chen, L., Rassenti, L. Z., DeBoever, C., Widhopf, G. F., Yu, J., Neuberg, D. S., Wierda, W. G., Rai, K. R., et al. (2016) · Blood · doi:10.1182/blood-2016-04-712562 · Cited by 157
Self-citationEvolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
Oakes, C. C., Claus, R., Gu, L., Assenov, Y., Hüllein, J., Zucknick, M., Bieg, M., Brocks, D., Bogatyrova, O., Schmidt, C. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0349 · Cited by 155
Self-citationQuality of life in chronic lymphocytic leukemia: an international survey of 1482 patients
Shanafelt, T. D., Bowen, D. A., Venkat, C., Slager, S. L., Zent, C. S., Kay, N. E., Reinalda, M. S., Sloan, J. A., & Call, T. G. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06791.x · Cited by 140
Alapat, D. V., Coviello‐Malle, J. M., Owens, R., Qu, P., Barlogie, B., Shaughnessy, J. D., & Lorsbach, R. B. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp59uorcyzevqo · Cited by 140
Thijssen, R., Slinger, E., Weller, K., Geest, C. R., Beaumont, T., van Oers, M. H. J., Kater, A. P., & Eldering, E. (2015) · Haematologica · doi:10.3324/haematol.2015.124560 · Cited by 134
Molecular underpinning of B‐cell anergy
Yarkoni, Y., Getahun, A., & Cambier, J. C. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00936.x · Cited by 131
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL
Slager, S. L., Rabe, K. G., Achenbach, S. J., Vachon, C. M., Goldin, L. R., Strom, S. S., Lanasa, M. C., Spector, L. G., Rassenti, L. Z., Leis, J. F., et al. (2010) · Blood · doi:10.1182/blood-2010-09-308205 · Cited by 128
Thompson, P. A., & Wierda, W. G. (2015) · Blood · doi:10.1182/blood-2015-08-634816 · Cited by 124
Self-citationBerndt, S. I., Camp, N. J., Skibola, C. F., Vijai, J., Wang, Z., Gu, J. H., Nieters, A., Kelly, R. S., Smedby, K. E. E., Monnereau, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms10933 · Cited by 120
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy
Packham, G., Krysov, S. V., Allen, A., Savelyeva, N., Steele, A. J., Forconi, F., & Stevenson, F. K. (2014) · Haematologica · doi:10.3324/haematol.2013.098384 · Cited by 116
Self-citationRacial differences in three major NHL subtypes: Descriptive epidemiology
Li, Y., Wang, Y., Wang, Z., Yi, D., & Ma, S. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2014.12.001 · Cited by 114
Liu, P., Xu, B., Shen, W., Zhu, H., Wu, W., Fu, Y., Chen, H., Dong, H., Zhu, Y., Miao, K., et al. (2011) · Leukemia · doi:10.1038/leu.2011.357 · Cited by 111
Cahill, N., Bergh, A.-C., Kanduri, M., Göransson‐Kultima, H., Mansouri, L., Isaksson, A., Ryan, F., Smedby, K. E. E., Juliusson, G., Sundström, C., et al. (2012) · Leukemia · doi:10.1038/leu.2012.245 · Cited by 111
Castro, J. E., Sandoval-Sus, J. D., Bole, J., Rassenti, L. Z., & Kipps, T. J. (2008) · Leukemia · doi:10.1038/leu.2008.214 · Cited by 109
Self-citationPresence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
Guièze, R., Robbe, P., Clifford, R. M., de Guibert, S., Pereira, B., Timbs, A., Dilhuydy, M., Cabes, M., Ysebaert, L., Burns, A., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647578 · Cited by 107
Getahun, A., Beavers, N. A., Larson, S. R., Shlomchik, M. J., & Cambier, J. C. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150537 · Cited by 106
Pei, L., Choi, J.-H., Liu, J., Lee, E.-J., McCarthy, B. A., Wilson, J. M., Speir, E. J., Awan, F. T., Tae, H., Arthur, G., et al. (2012) · Epigenetics · doi:10.4161/epi.20237 · Cited by 99
Khouri, I. F., Bassett, R. L., Poindexter, N. J., O'Brien, S. M., Bueso-Ramos, C., Hsu, Y., Ferrajoli, A., Keating, M. J., Champlin, R. E., & Fernández-Viña, M. (2011) · Cancer · doi:10.1002/cncr.26091 · Cited by 99
Self-citationDhalla, F., Lucas, M., Schuh, A., Bhole, M. V., Jain, R., Patel, S. Y., Misbah, S., & Chapel, H. M. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-9995-5 · Cited by 96
IL-4 enhances expression and function of surface IgM in CLL cells
Aguilar-Hernández, M., Blunt, M. D., Dobson, R. C., Yeomans, A., Thirdborough, S. M., Larráyoz, M., Smith, L. D., Linley, A. J., Strefford, J. C., Davies, A. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682906 · Cited by 95
Self-citationVlad, A., Deglesne, P., Letestu, R., Saint-Georges, S., Chevallier, N., Baran‐Marszak, F., Varin‐Blank, N., Cymbalista, F., & Ledoux, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4750 · Cited by 93
The impact of SF3B1 mutations in CLL on the DNA-damage response
Raa, G. D. T., Derks, I. A. M., Navrkalová, V., Skowrońska, A., Moerland, P. D., van Laar, J., Oldreive, C., Monsuur, H. N., Trbušek, M., Malčíková, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.318 · Cited by 91
Tadmor, T., Aviv, A., & Polliack, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq308 · Cited by 91
Yu, J., Chen, L., Cui, B., Wu, C. C. N., Choi, M. Y., Chen, Y., Zhang, L., Rassenti, L. Z., Widhopf, G. F., & Kipps, T. J. (2016) · Leukemia · doi:10.1038/leu.2016.368 · Cited by 90
Self-citationFecteau, J.-F., Corral, L. G., Ghia, E. M., Gaidarova, S., Futalan, D., Bharati, I. S., Cathers, B. E., Schwaederle, M. C., Cui, B., Lopez‐Girona, A., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559591 · Cited by 88
Self-citationThe Pax-5 Gene: A Pluripotent Regulator of B-cell Differentiation and Cancer Disease
O'Brien, P., Morin, P., Ouellette, R. J., & Robichaud, G. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1874 · Cited by 85
Dyke, D. L. V., Werner, L. L., Rassenti, L. Z., Neuberg, D. S., Ghia, E., Heerema, N. A., Cin, P. D., Aquila, M. D., Sreekantaiah, C., Greaves, A. W., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13933 · Cited by 82
Self-citationSomatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL
Wang, L., Shalek, A. K., Lawrence, M. S., Ding, R., Gaublomme, J. T., Pochet, N. L. M. M., Stojanov, P., Sougnez, C. L., Shukla, S. A., Stevenson, K. E., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552067 · Cited by 81
Self-citationGhia, E. M., Jain, S., Widhopf, G. F., Rassenti, L. Z., Keating, M. J., Wierda, W. G., Gribben, J. G., Brown, J. R., Rai, K. R., Byrd, J. C., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130229 · Cited by 80
Self-citationTCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia
Balatti, V., Rizzotto, L., Miller, C. R., Palamarchuk, A., Fadda, P., Pandolfo, R., Rassenti, L. Z., Hertlein, E. K., Ruppert, A. S., Lozanski, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500010112 · Cited by 79
Self-citationRichter syndrome: pathogenesis and management
Rossi, D., & Gaïdano, G. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.012 · Cited by 79
O’Hayre, M., Salanga, C. L., Kipps, T. J., Messmer, D., Dorrestein, P. C., & Handel, T. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011716 · Cited by 78
Self-citationMauro, F. R., Chauvie, S., Paoloni, F. P., Biggi, A., Cimino, G. G., Rago, A., Gentile, M., Morabito, F., Coscia, M., Bellò, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.21 · Cited by 76
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
Wang, J., Khiabanian, H., Rossi, D., Fabbri, G., Gattei, V., Forconi, F., Laurenti, L., Marasca, R., Poeta, G. D., Foà, R., et al. (2014) · eLife · doi:10.7554/elife.02869 · Cited by 73
Fludarabine: A review of the clear benefits and potential harms
Lukenbill, J., & Kalaycio, M. E. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.05.004 · Cited by 72
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics
Landau, D. A., & Wu, C. J. (2013) · Genome Medicine · doi:10.1186/gm451 · Cited by 71
Self-citationOjha, J., Codd, V., Nelson, C. P., Samani, N. J., Smirnov, I. V., Madsen, N. R., Hansen, H. M., de Smith, A. J., Bracci, P. M., Wiencke, J. K., et al. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-1329 · Cited by 71
Coelho, V., Krysov, S. V., Steele, A. J., Sánchéz‐Hidalgo, M., Johnson, P., Chana, P. S., Packham, G., Stevenson, F. K., & Forconi, F. (2013) · Blood · doi:10.1182/blood-2013-02-485425 · Cited by 69
Self-citationJames, D. F., Werner, L. L., Brown, J. R., Wierda, W. G., Barrientos, J. C., Castro, J. E., Greaves, A. W., Johnson, A. J., Rassenti, L. Z., Rai, K. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5890 · Cited by 68
Self-citationA role for IRF4 in the development of CLL
Shukla, V., Ma, S., Hardy, R. R., Joshi, S. S., & Lu, R. (2013) · Blood · doi:10.1182/blood-2013-03-492769 · Cited by 58
Deniger, D. C., Yu, J., Huls, M. H., Figliola, M. J., Mi, T., Maiti, S. N., Widhopf, G. F., Hurton, L. V., Thokala, R., Singh, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128151 · Cited by 56
Self-citationEtet, P. F. S., Vecchio, L., & Kamdje, A. H. N. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.03.008 · Cited by 52
Guo, A., Lu, P., Galanina, N., Nabhan, C., Smith, S. M., Coleman, M., & Wang, Y. L. (2015) · Oncotarget · doi:10.18632/oncotarget.6727 · Cited by 52
New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms
Awan, F. T., & Byrd, J. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1889 · Cited by 49
Falco, F. D., Sabatini, R., Papa, B. D., Falzetti, F., Ianni, M. D., Sportoletti, P., Baldoni, S., Screpanti, I., Marconi, P., & Rosati, E. (2015) · Oncotarget · doi:10.18632/oncotarget.4116 · Cited by 48
Decker, S., Zirlik, K., Djebatchie, L., Hartmann, D., Ihorst, G., Schmitt-Graeff, A. H., Herchenbach, D., Jumaa, H., Warmuth, M., Veelken, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-359075 · Cited by 46
Nabhan, C., Aschebrook‐Kilfoy, B., Chiu, B. C. ‐., Smith, S. M., Shanafelt, T. D., Evens, A. M., & Kay, N. E. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.898758 · Cited by 45
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia
Veronese, A., Pepe, F., Chiacchia, J., Pagotto, S., Lanuti, P., Veschi, S., Marco, M. D., D’Argenio, A., Innocenti, I., Vannata, B., et al. (2014) · Leukemia · doi:10.1038/leu.2014.139 · Cited by 32
Self-citationSchinasi, L. H., Roos, A. J. D., Ray, R. M., Edlefsen, K. L., Parks, C. G., Howard, B. V., Meliker, J. R., Bonner, M. R., Wallace, R. B., & LaCroix, A. Z. (2015) · Annals of Epidemiology · doi:10.1016/j.annepidem.2015.08.002 · Cited by 32
Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia
Spadaro, G., Pecoraro, A., Renzo, A. D., Pepa, R. D., & Genovese, A. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.04.001 · Cited by 29
Vitale, C., Falchi, L., ten Hacken, E., Gao, H., Shaim, H., Roosbroeck, K. V., Călin, G. A., O'Brien, S. M., Faderl, S., Wang, X., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2476 · Cited by 27
Self-citationChávez, J. C., Piris‐Villaespesa, M., Dalia, S. M., Powers, J. J., Turba, E., Nodzon, L., Komrokji, R. S., Sokol, L., Locke, F. L., Lancet, J. E., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.05.012 · Cited by 24
Pepper, C. J., Buggins, A. G. S., Jones, C. H., Walsby, E. J., Forconi, F., Pratt, G., Devereux, S., Stevenson, F. K., & Fegan, C. (2014) · Leukemia · doi:10.1038/leu.2014.308 · Cited by 23
Self-citationTreating chronic lymphocytic leukemia with thalidomide and lenalidomide
Giannopoulos, K., Mertens, D., & Stilgenbauer, S. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.635644 · Cited by 22
Woyach, J. A. (2015) · Hematology · doi:10.1182/asheducation-2015.1.355 · Cited by 21
A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B‐cells
Medves, S., Auchter, M., Chambeau, L., Gazzo, S., Poncet, D., Grangier, B., Verney, A., Moussay, E., Ammerlaan, W., Brisou, G., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13995 · Cited by 21
Johnsen, H. E., Bergkvist, K. S., Schmitz, A., Kjeldsen, M. K., Hansen, S. M., Gaihede, M. L., Nørgaard, M. A., Bæch, J., Grønholdt, M.-L. M., Jensen, F. S., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.839785 · Cited by 20
Radivoyevitch, T., Sachs, R. K., Gale, R. P., Smith, M. R., & Hill, B. T. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.02.008 · Cited by 13
Cited by
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
Zimmermann, M., Murina, O., Reijns, M. A. M., Agathanggelou, A., Challis, R., Tarnauskaitė, Ž., Muir, M., Fluteau, A., Aregger, M., McEwan, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0291-z · Cited by 401
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
Dong, Y., Shi, O., Zeng, Q., Lu, X., Wang, W., Li, Y., & Wang, Q. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00170-6 · Cited by 336
Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01580 · Cited by 309
Self-citationNovel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
Sierksma, A., Lu, A., Mancuso, R., Fattorelli, N., Thrupp, N., Salta, E., Zoco, J., Blum, D., Buée, L., De Strooper, B., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910606 · Cited by 291
Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99386 · Cited by 52
Metadata
- Authors
- Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K.
- Venue
- Nature Reviews Disease Primers
- Published
- 2017-01-19
- Volume
- 3
- Issue
- 1
- Pages
- 16096-16096
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W2204986825
- Cited by
- 517
- References
- 180
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.